PDF herunterladen
CC BY-NC-ND 4.0 · Indian Journal of Neurosurgery 2021; 10(01): 061-064
DOI: 10.1055/s-0041-1726134
Original Article

Outcomes of Transsphenoidal Surgery in Growth Hormone-Secreting Pituitary Adenomas

Oleksandr Voznyak
1   Centre of Neurosurgery, Clinical Hospital “Feofaniya,” Kyiv, Ukraine
,
Andrii Lytvynenko
1   Centre of Neurosurgery, Clinical Hospital “Feofaniya,” Kyiv, Ukraine
,
Oleg Maydannyk
1   Centre of Neurosurgery, Clinical Hospital “Feofaniya,” Kyiv, Ukraine
,
Roman Ilyuk
1   Centre of Neurosurgery, Clinical Hospital “Feofaniya,” Kyiv, Ukraine
,
Yaroslav Zinkevych
1   Centre of Neurosurgery, Clinical Hospital “Feofaniya,” Kyiv, Ukraine
,
Nazarii Hryniv
2   Department of Neurosurgery, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
› Institutsangaben Funding None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Growth hormone (GH)-secreting pituitary adenomas (PA) make up 15 to 20% of total amount of hormonally active adenomas. In addition to acromegaly and gigantism, these tumors cause deep metabolic disturbances. Its systemic impact leads to increased mortality ratio of 1.32 compared with general population. Surgical removal remains the priority treatment option in controlling acromegaly and provides endocrinologic remission in up to 72% patients. A total of 92 patients were included in the study. All surgeries were performed via microscopic transsphenoidal approach (TSA) by the senior author in our institution between December 2009 and October 2019. Only patients who were followed-up with 75 g oral glucose tolerance tests (OGTTs), GH, and insulin-like growth factor I (IFG-I) measurements preoperatively, 1 week, and every 6 months postoperatively were analyzed. Based on standard preoperative 1.5-T MR imaging with contrast enhancement, the adenomas were identified and distributed according to the size and KNOSP classification. The efficacy depends on KNOSP grade, which is directly correlated with invasiveness to cavernous sinus (CS). Grades 3 and 4 are unfavorable factors influencing prognosis. Excluding grade 0 adenomas, as the surgery was not difficult with the excellent outcomes, we reached 75% (36 out of 48) remission in grade 1 to 2 groups. In contrast, only 17% (2 out of 12) had successful outcomes after surgery alone. In conclusion, the study demonstrates the efficiency of TS surgery in patients with confirmed GH-secreting PA.

Keywords

pituitary adenoma - acromegaly - transsphenoidal approach


Publikationsverlauf

Artikel online veröffentlicht:
11. März 2021

© 2021. Neurological Surgeons’ Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Melmed S, Colao A, Barkan A. et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94 (05) 1509-1517
    CrossrefPubMedGoogle Scholar
  • 2 Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro-oncol 2017; 19 (06) 762-773
    PubMedGoogle Scholar
  • 3 Georgia N, Niki K. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia: Elsevier 2016: 188-208
  • 4 Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008; 93 (01) 61-67
    CrossrefPubMedGoogle Scholar
  • 5 Abreu A, Tovar AP, Castellanos R. et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 2016; 19 (04) 448-457
    CrossrefPubMedGoogle Scholar
  • 6 Hamurcu Z, Cakir I, Donmez-Altuntas H. et al. Micronucleus evaluation in mitogen-stimulated lymphocytes of patients with acromegaly. Metabolism 2011; 60 (11) 1620-1626
    CrossrefPubMedGoogle Scholar
  • 7 Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41 (01) 95-102
    CrossrefPubMedGoogle Scholar
  • 8 Melmed S, Casanueva F, Cavagnini F. et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153 (06) 737-740
    CrossrefPubMedGoogle Scholar
  • 9 Starke RM, Raper DMS, Payne SC. Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013; 98 (08) 3190-3198
    CrossrefPubMedGoogle Scholar
  • 10 Moon JH, Kim EH, Kim SH. Snare technique for the remodeling of the redundant arachnoid pouch to prevent cerebrospinal fluid rhinorrhea and hematoma collection during transsphenoidal surgery for suprasellar-extended pituitary tumors. J Neurosurg 2016; 125 (06) 1443-1450
    CrossrefPubMedGoogle Scholar
  • 11 Kim EH, Roh TH, Park HH, Moon JH, Hong JB, Kim SH. Direct suture technique of normal gland edge on the incised dura margin to repair the intraoperative cerebrospinal fluid leakage from the arachnoid recess during transsphenoidal pituitary tumor surgery. Neurosurgery 2015; 11 (Suppl. 02) 26-31, discussion 31
    PubMedGoogle Scholar
  • 12 Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2010; 6 (04) 214-223
    CrossrefPubMedGoogle Scholar
  • 13 Lorenzo-Solar M, Castro A, Peino R, Fernandez-Alvarez J, Dieguez C, Casanueva FF. Can treatment with somatostatin analogs replace neurosurgery?. J Endocrinol Invest 2005; 28 (11, Suppl International) 48-52
    PubMedGoogle Scholar
  • 14 van der Lely AJ, Biller BMK, Brue T. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97 (05) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 15 Minniti G, Jaffrain-Rea M-L, Osti M. et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005; 62 (02) 210-216
    CrossrefPubMedGoogle Scholar
  • 16 Mitsumori M, Shrieve DC, Alexander E III. et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998; 42 (03) 573-580
    CrossrefPubMedGoogle Scholar
  • 17 Stofko DL, Nickles T, Sun H, Dehdashti AR. The value of immediate postoperative MR imaging following endoscopic endonasal pituitary surgery. Acta Neurochir (Wien) 2014; 156 (01) 133-140
    CrossrefPubMedGoogle Scholar
  • 18 Katznelson L, Laws Jr ER, Melmed S. et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (11) 3933-3951
    CrossrefPubMedGoogle Scholar
  • 19 Lonser RR, Kindzelski BA, Mehta GU. Jane JA Jr, Oldfield EH. Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab 2010; 95 (09) 4192-4196
    CrossrefPubMedGoogle Scholar
  • 20 Wilson CB. Neurosurgical management of large and invasive pituitary tumors. In: George TT, William FC, eds. Clinical Management of Pituitary Disorders. New York, NY: Raven Press 1979: 335-342
  • 21 Hofstetter CP, Shin BJ, Mubita L. et al. Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus 2011; 30 (04) E10
    CrossrefPubMedGoogle Scholar
  • 22 Shin SS, Tormenti MJ, Paluzzi A. et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary 2013; 16 (04) 435-444
    CrossrefPubMedGoogle Scholar
  • 23 Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly. Nat Rev Endocrinol 2011; 7 (05) 291-300
    CrossrefPubMedGoogle Scholar